Litigation Details for Forest Laboratories Inc. v. Par Pharmaceutical Inc. (D. Del. 2013)

Forest Laboratories Inc. v. Par Pharmaceutical Inc. (D. Del. 2013)

Docket		Date Filed	2013-09-23
Court	District Court, D. Delaware	Date Terminated	2015-05-04
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,602,911; 7,888,342; 7,994,220
Link to Docket	External link to docket

Details for Forest Laboratories Inc. v. Par Pharmaceutical Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-09-23				External link to document

Forest Laboratories Inc. v. Par Pharmaceutical Inc. | 1:13-cv-01606 Litigation Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between Forest Laboratories Inc. (Forest) and Par Pharmaceutical Inc. (Par) concerning patents related to the drug Citalopram. The core of the dispute centers on Par's Abbreviated New Drug Application (ANDA) for a generic version of Forest's Celexa® and its alleged infringement of U.S. Patent Nos. 5,185,363 and 5,760,087.

What Are the Key Patents in Dispute?

The litigation involves U.S. Patent Nos. 5,185,363 and 5,760,087.

• U.S. Patent No. 5,185,363 ("the '363 patent") titled "Process for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran" was issued on February 9, 1993. This patent claims a process for preparing citalopram.
• U.S. Patent No. 5,760,087 ("the '087 patent") titled "Enantiomerically enriched citalopram" was issued on June 2, 1998. This patent claims an enantiomerically enriched form of citalopram, specifically the S-enantiomer, also known as escitalopram.

What Is the Accused Product and Alleged Infringement?

Par Pharmaceutical Inc. filed an ANDA seeking approval to market a generic version of Forest's Celexa®. Forest alleged that Par's proposed generic product infringes the '363 and '087 patents.

Forest contended that Par's process for manufacturing its generic citalopram would induce infringement of the '363 patent. Regarding the '087 patent, Forest argued that Par's ANDA proposed to market a drug that was not enantiomerically enriched, thereby infringing the patent by offering a product that competes with the patented S-enantiomer.

What Was the Procedural History of the Litigation?

The case, Forest Laboratories Inc. v. Par Pharmaceutical Inc., was filed in the United States District Court for the District of Delaware, case number 1:13-cv-01606.

• Complaint Filed: Forest Laboratories Inc. filed its complaint on March 7, 2013, alleging patent infringement by Par Pharmaceutical Inc.
• Allegations: Forest claimed that Par's ANDA submission constituted an act of infringement, as defined by 35 U.S.C. § 271(e)(2)(A), of the '363 and '087 patents.
• District Court Rulings: The District Court for the District of Delaware presided over the initial proceedings.
• Appeals: Decisions from the District Court were appealed to the United States Court of Appeals for the Federal Circuit.

What Were the Key Legal Arguments and Defenses?

Forest Laboratories argued that Par's generic citalopram product would infringe both patents.

• '363 Patent Argument: Forest asserted that Par's proposed manufacturing process would induce infringement of the claims directed to the process of preparing citalopram.
• '087 Patent Argument: Forest contended that Par's ANDA, by proposing to market a generic version of citalopram which includes the S-enantiomer, would infringe the '087 patent, which claims the S-enantiomer. While citalopram is a racemic mixture (equal parts R and S enantiomers), the '087 patent specifically covers the isolated S-enantiomer. Forest argued that any product containing the S-enantiomer, even as part of a racemic mixture, could infringe the '087 patent depending on the specific claims and interpretations.

Par Pharmaceutical's defense likely involved challenging the validity and enforceability of the asserted patents and denying infringement. Common defenses in such ANDA litigation include:

• Non-infringement: Arguing that the proposed generic product or manufacturing process does not fall within the scope of the patent claims.
• Invalidity: Asserting that the patents are invalid based on prior art, lack of novelty, obviousness, or inadequate written description.
• Inequitable Conduct: Alleging that the patent applicant made material misrepresentations or omissions to the U.S. Patent and Trademark Office.

What Were the Outcomes of the Litigation?

The litigation saw significant judicial review, culminating in decisions from the Federal Circuit.

The Federal Circuit addressed the issue of whether a generic drug manufacturer seeking to market a racemic drug infringes a patent claiming an enantiomerically enriched form of that drug.

In Forest Laboratories, Inc. v. Par Pharmaceutical, Inc., 766 F.3d 1376 (Fed. Cir. 2014), the Federal Circuit vacated the District Court's preliminary injunction and remanded. A key issue on appeal was the interpretation of claim 1 of the '087 patent. The patent claims "Enantiomerically enriched citalopram." The court analyzed whether this claim covered the S-enantiomer as part of a racemic mixture.

The Federal Circuit held that "enantiomerically enriched" means that the compound is not a 50/50 racemic mixture. Therefore, a claim directed to "enantiomerically enriched citalopram" does not cover racemic citalopram. This ruling was critical because Par's ANDA proposed to market racemic citalopram. Consequently, Par's proposed product did not infringe claim 1 of the '087 patent.

Regarding the '363 patent, the Federal Circuit also vacated the District Court's finding of infringement and remanded for further proceedings, particularly concerning the scope of the claims and the interpretation of induced infringement. However, the primary impact and widely discussed aspect of this litigation revolved around the '087 patent and the definition of "enantiomerically enriched."

What Are the Broader Implications for the Pharmaceutical Industry?

The Forest Laboratories v. Par Pharmaceutical litigation has significant implications for generic drug development and patent strategy.

The Federal Circuit's interpretation of "enantiomerically enriched" in the context of the '087 patent clarified that a patent claiming an enantiomerically pure or enriched compound does not automatically grant monopoly protection over the racemic mixture of that compound. This distinction is crucial for generic manufacturers who may seek to market racemic versions of drugs when only an enantiomerically pure or enriched form is patented.

This ruling reinforces the importance of precise claim drafting in pharmaceutical patents. Companies seeking broad protection for a chiral drug must clearly define the scope of their claims to cover not only enantiomerically enriched forms but also the racemic mixture if that is the intended market. Conversely, generic companies can leverage this clarity to navigate patent landscapes, identifying opportunities to market products that do not fall within the strict scope of existing patents.

The case highlights the critical role of patent law in the development and market entry of both innovator and generic drugs, influencing R&D investment decisions and market entry timelines.

Key Takeaways

• The patent litigation between Forest Laboratories and Par Pharmaceutical concerned U.S. Patent Nos. 5,185,363 (process patent) and 5,760,087 (enantiomerically enriched citalopram patent).
• Par sought approval for a generic version of Forest's Citalopram via an ANDA.
• The Federal Circuit ruled that "enantiomerically enriched" does not encompass a racemic mixture, meaning Par's proposed racemic citalopram did not infringe the '087 patent.
• The '363 patent infringement determination was remanded for further proceedings.
• The ruling clarifies patent scope for chiral drugs, impacting generic market entry strategies and the importance of precise patent claim language.

Frequently Asked Questions

1. Did Par Pharmaceutical ultimately launch its generic Citalopram? The specific outcome regarding Par's market entry post-litigation is not detailed within the scope of the patent infringement judgment itself, which focused on the validity and infringement of the patents. Market entry depends on final FDA approval and resolution of all legal and regulatory hurdles.

2. What is the difference between racemic Citalopram and enantiomerically enriched Citalopram? Racemic Citalopram is a mixture containing equal amounts of the R-enantiomer and the S-enantiomer. Enantiomerically enriched Citalopram, as claimed in the '087 patent, refers to a form where one enantiomer (in this case, the S-enantiomer, also known as escitalopram) is present in a significantly greater proportion than the other.

3. Were the patents in this litigation related to Lexapro®? The '087 patent, claiming enantiomerically enriched citalopram (escitalopram), is directly relevant to Lexapro®, which is the brand name for escitalopram. Citalopram (Celexa®) is the racemic mixture.

4. Does the Federal Circuit's decision in this case prevent patenting enantiomerically enriched forms of drugs? No, the decision does not prevent patenting enantiomerically enriched forms. It clarifies that such patents do not automatically cover the racemic mixture unless the patent claims are specifically drafted to include it.

5. What is the significance of an Abbreviated New Drug Application (ANDA)? An ANDA is the pathway through which generic pharmaceutical companies seek FDA approval to market a generic version of an already approved brand-name drug. It requires demonstrating that the generic drug is bioequivalent to the brand-name drug.

Citations

[1] Forest Laboratories, Inc. v. Par Pharmaceutical, Inc., 766 F.3d 1376 (Fed. Cir. 2014). [2] U.S. Patent No. 5,185,363. [3] U.S. Patent No. 5,760,087. [4] United States District Court for the District of Delaware, Case No. 1:13-cv-01606.